Business Context and Reporting Period
This Form 8-K filing by Gossamer Bio, Inc. (GOSS) reports a significant change in executive leadership effective November 16, 2020. The company is an emerging growth company incorporated in Delaware with principal offices in San Diego, California.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Leadership Transition: Faheem Hasnain, Co-Founder and current Chairman, was appointed President and Chief Executive Officer, replacing Sheila Gujrathi, M.D.
- Board Composition: Dr. Gujrathi ceased serving as a member of the Board of Directors effective November 16, 2020, though she will continue in an advisory role.
- Compensation Adjustments:
- Dr. Gujrathi: Entitled to cash and healthcare severance benefits per her 2018 Employment Letter. She received 18 months of accelerated vesting on outstanding restricted stock. All remaining unvested restricted stock, stock options, and RSUs were forfeited and cancelled.
- Mr. Hasnain: Annual base salary set at $572,000 with a target annual bonus of 50% of base salary. Future stock option or RSU awards are expected but not yet determined.
Outlook, Risks, and Contingencies
The filing outlines specific severance contingencies for Mr. Hasnain under the Amended Hasnain Letter Agreement. If terminated without cause or resigning for good reason, he is eligible for 12 months of base salary (increasing to 18 months if within 12 months of a change in control), a pro-rated target bonus (non-prorated if within 12 months of a change in control), and health coverage for up to 12 months (increasing to 18 months if within 12 months of a change in control). The filing notes that full details of the Transition Agreement and Amended Hasnain Letter Agreement will be filed as exhibits to the 2020 Form 10-K.
Investor Verification Checklist
- Verify the exact terms of the Transition Agreement and Amended Hasnain Letter Agreement in the upcoming 2020 Form 10-K exhibits.
- Confirm the specific equity awards (stock options/RSUs) to be granted to Mr. Hasnain, as these were not determined at the time of filing.
- Review the impact of Dr. Gujrathi's departure on the company's strategic direction and advisory capabilities.
- Monitor future filings for any change in control events that would trigger enhanced severance provisions for Mr. Hasnain.